Comparing Early Intra-aortic Balloon Pump Use Versus Standard Care in Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock

What this Trial Is About

Researchers are evaluating the effect of early use of an Intra-aortic Balloon Pump IABP for left ventricular unloading in patients with cardiogenic shock who are receiving venoarterial extracorporeal membrane oxygenation VA-ECMO. This multicenter, randomized trial aims to determine whether early IABP use improves outcomes compared to the conventional approach without mechanical unloading. The study will include 358 patients to assess the impact on 30-day mortality and other clinical outcomes. Participants will be randomly assigned to one of two groups the ECMOIABP group, receiving IABP within 6 hours after VA-ECMO starts, or the ECMO group, which will not receive mechanical unloading within 6 hours. The main focus is on early intervention to unload the left ventricle in patients undergoing VA-ECMO treatment for cardiogenic shock. During the study, researchers will monitor participants for 30 days, measuring mortality, ability to wean from VA-ECMO, left ventricular function, rates of complications such as stroke, bleeding, infections, and length of hospital and intensive care stays. Various laboratory markers and imaging outcomes will also be evaluated to assess heart function and recovery. The trial intends to provide detailed information on the benefits and risks of early IABP use in this patient population.

Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation